Duolingo Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? Duolingo Inc trades at $151.49 (market cap $7.10B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Duolingo Inc is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| DUOL | RLAY | |
|---|---|---|
Market Cap | $7.10B | $3.94B |
Volume | 922,471 | 3,432,928 |
Sector | Technology | Health |
52-Week High | $341.08 | $20.75 |
52-Week Low | $90.03 | $6.03 |
Typical Hold Time | 137 Days | 0 Days |
Enterprise Value | $5.87B | $3.06B |
Signals from Pluang's Aura AI — not financial advice
DUOL trades at $151.72, up 2.42% today, with a bullish technical outlook and strong support near $149. The company reported robust fundamentals, with Q2 2026 EPS beating expectations at $0.66 versus $0.604, and revenue growth accelerating to $1.04 billion in 2025. Operating cash flow surged to $387.82 million, reflecting strong operational efficiency.
The stock presents a compelling growth story with high net margins of 35.87% and consistent earnings beats, though valuation multiples like EV/EBITDA of 33.96 suggest premium pricing. Key risks include insider selling and competitive pressures in edtech. Analyst consensus is mixed with a $140.63 price target, indicating cautious optimism amid near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →